
The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.
In a follow-up to a final rule about Medicare Part D's low-income benchmark, the Centers for Medicare & Medicaid Services said it made some mathematical errors.
The Centers for Medicare & Medicaid Services admitted in a correction posted in the April 17
To see more Daily News articles,
To go to the Drug Topics homepage,






